{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:09:34Z","timestamp":1789546174967,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00259-025-07630-3","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:11:02Z","timestamp":1761955862000},"page":"2245-2256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The diagnostic accuracy of [99mTc]Tc-PSMA SPECT\/CT for recurrent prostate cancer based on individual patient attributes"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0938-5459","authenticated-orcid":false,"given":"Knut","family":"Liepe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony Matti","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Baehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"7630_CR1","doi-asserted-by":"publisher","first-page":"e2456825","DOI":"10.1001\/jamanetworkopen.2024.56825","volume":"8","author":"EL Van Blarigan","year":"2025","unstructured":"Van Blarigan EL, McKinley MA, Washington SL III, Cooperberg MR, Kenfield SA, Cheng I, et al. Trends in prostate cancer incidence and mortality rates. JAMA Netw Open. 2025;8:e2456825\u2013e. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.56825.","journal-title":"JAMA Netw Open"},{"key":"7630_CR2","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.21873\/anticanres.17623","volume":"45","author":"R Aizawa","year":"2025","unstructured":"Aizawa R, Ogata T, Goto T, Otani T, Nakamura K, Kita Y, et al. Clinical outcomes of metastasis-directed therapy for oligo-metastatic prostate cancer diagnosed using PSMA-PET\/CT or whole-body MRI. Anticancer Res. 2025;45:2515\u201325. https:\/\/doi.org\/10.21873\/anticanres.17623.","journal-title":"Anticancer Res"},{"key":"7630_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2024.100762","volume":"46","author":"J Chamois","year":"2024","unstructured":"Chamois J, Septans AL, Schipman B, Gross E, Blanchard N, Passerat V, et al. Metastases-directed radiotherapy in castration resistant oligo metastatic prostate cancer: a multicentric retrospective study from the French group colib. Clin Transl Radiat Oncol. 2024;46:100762. https:\/\/doi.org\/10.1016\/j.ctro.2024.100762.","journal-title":"Clin Transl Radiat Oncol"},{"key":"7630_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"7630_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2967\/jnumed.117.197160","volume":"59","author":"PJ Roach","year":"2018","unstructured":"Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, et al. The impact of 68Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. J Nucl Med. 2018;59:82. https:\/\/doi.org\/10.2967\/jnumed.117.197160.","journal-title":"J Nucl Med"},{"key":"7630_CR6","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/s0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(20)30314-7.","journal-title":"Lancet"},{"key":"7630_CR7","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid 2025. ISBN 978-94-92671-29-5."},{"key":"7630_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00850-y","author":"A Mari","year":"2024","unstructured":"Mari A, Cadenar A, Giudici S, Cianchi G, Albisinni S, Autorino R, et al. A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET\/CT in the initial staging of prostate cancer. Prostate Cancer Prostatic Dis. 2024. https:\/\/doi.org\/10.1038\/s41391-024-00850-y.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"7630_CR9","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1007\/s00259-021-05189-3","volume":"48","author":"A Afshar-Oromieh","year":"2021","unstructured":"Afshar-Oromieh A, da Cunha ML, Wagner J, Haberkorn U, Debus N, Weber W, et al. Performance of [(68)Ga]Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients. Eur J Nucl Med Mol Imaging. 2021;48:2925\u201334. https:\/\/doi.org\/10.1007\/s00259-021-05189-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7630_CR10","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.18632\/oncotarget.27239","volume":"10","author":"MA Hoffmann","year":"2019","unstructured":"Hoffmann MA, Buchholz HG, Wieler HJ, H\u00f6fner T, M\u00fcller-H\u00fcbenthal J, Trampert L, et al. The positivity rate of 68Gallium-PSMA-11 ligand PET\/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Oncotarget. 2019;10:6124\u201337. https:\/\/doi.org\/10.18632\/oncotarget.27239.","journal-title":"Oncotarget"},{"key":"7630_CR11","doi-asserted-by":"publisher","first-page":"6271","DOI":"10.3390\/curroncol30070464","volume":"30","author":"L Garc\u00eda-Zoghby","year":"2023","unstructured":"Garc\u00eda-Zoghby L, Lucas-Lucas C, Amo-Salas M, Soriano-Castrej\u00f3n \u00c1M, Garc\u00eda-Vicente AM. Head-to-head comparison of [(18)F]F-choline and imaging of prostate-specific membrane antigen, using [(18)F]DCFPyL PET\/CT, in patients with biochemical recurrence of prostate cancer. Curr Oncol. 2023;30:6271\u201388. https:\/\/doi.org\/10.3390\/curroncol30070464.","journal-title":"Curr Oncol"},{"key":"7630_CR12","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1177\/02841851231184210","volume":"64","author":"YY Yang","year":"2023","unstructured":"Yang YY, Liu ZM, Peng RC. Diagnostic performance of 18F-labeled PSMA PET\/CT in patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Acta Radiol. 2023;64:2791\u2013801. https:\/\/doi.org\/10.1177\/02841851231184210.","journal-title":"Acta Radiol"},{"key":"7630_CR13","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.eururo.2015.11.036","volume":"69","author":"S Loeb","year":"2016","unstructured":"Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P. Evaluation of the 2015 Gleason grade groups in a nationwide population-based cohort. Eur Urol. 2016;69:1135\u201341. https:\/\/doi.org\/10.1016\/j.eururo.2015.11.036.","journal-title":"Eur Urol"},{"key":"7630_CR14","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/PAT.0000000000000318","volume":"47","author":"B Delahunt","year":"2015","unstructured":"Delahunt B, Egevad L, Srigley JR, Steigler A, Murray JD, Atkinson C, et al. Validation of international society of urological pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 \u2018RADAR\u2019 trial clinical data. Pathology. 2015;47:520\u20135. https:\/\/doi.org\/10.1097\/PAT.0000000000000318.","journal-title":"Pathology"},{"key":"7630_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2019.100151","volume":"20","author":"L Ranasinghe","year":"2019","unstructured":"Ranasinghe L, Cotogno P, Ledet E, Bordlee B, Degeyter K, Nguyen N, et al. Relationship between serum markers and volume of liver metastases in castration-resistant prostate cancer. Cancer Treatment and Research Communications. 2019;20:100151. https:\/\/doi.org\/10.1016\/j.ctarc.2019.100151.","journal-title":"Cancer Treatment and Research Communications"},{"key":"7630_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/rlu.0000000000001991","volume":"43","author":"C Schmidkonz","year":"2018","unstructured":"Schmidkonz C, Cordes M, Beck M, Goetz TI, Schmidt D, Prante O, et al. SPECT\/CT with the PSMA ligand 99mTc-MIP-1404 for whole-body primary staging of patients with prostate cancer. Clin Nucl Med. 2018;43:225\u201331. https:\/\/doi.org\/10.1097\/rlu.0000000000001991.","journal-title":"Clin Nucl Med"},{"key":"7630_CR17","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1159\/000520684","volume":"106","author":"F Crocerossa","year":"2022","unstructured":"Crocerossa F, Carbonara U, Parekh J, Urdaneta A, Weprin S, Damiano R, et al. PSA and PSA kinetics as predictors for 18F-fluciclovine PET\/CT positivity in biochemically recurrent prostate cancer. Urol Int. 2022;106:920\u20137. https:\/\/doi.org\/10.1159\/000520684.","journal-title":"Urol Int"},{"key":"7630_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-65969-3","volume":"14","author":"S Sakamoto","year":"2024","unstructured":"Sakamoto S, Sato K, Kimura T, Matsui Y, Shiraishi Y, Hashimoto K, et al. PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer. Sci Rep. 2024;14:15307. https:\/\/doi.org\/10.1038\/s41598-024-65969-3.","journal-title":"Sci Rep"},{"key":"7630_CR19","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/jco.2008.18.1685","volume":"27","author":"AJ Vickers","year":"2009","unstructured":"Vickers AJ, Savage C, O\u2019Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2009;27:398\u2013403. https:\/\/doi.org\/10.1200\/jco.2008.18.1685.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"7630_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77:403\u201317. https:\/\/doi.org\/10.1016\/j.eururo.2019.01.049.","journal-title":"Eur Urol"},{"key":"7630_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-024-01190-7","volume":"15","author":"J Heilinger","year":"2025","unstructured":"Heilinger J, Roth KS, Weis H, Fink A, Weindler J, Dietlein F, et al. Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy. EJNMMI Res. 2025;15:4. https:\/\/doi.org\/10.1186\/s13550-024-01190-7.","journal-title":"EJNMMI Res"},{"key":"7630_CR22","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/mnm.0000000000001361","volume":"42","author":"B Singh","year":"2021","unstructured":"Singh B, Sharma S, Bansal P, Hooda M, Singh H, Parihar AS, et al. Comparison of the diagnostic utility of 99mTc-PSMA scintigraphy versus 68Ga-PSMA-11 PET\/CT in the detection of metastatic prostate cancer and dosimetry analysis: a gamma-camera-based alternate prostate-specific membrane antigen imaging modality. Nucl Med Commun. 2021;42:482\u20139. https:\/\/doi.org\/10.1097\/mnm.0000000000001361.","journal-title":"Nucl Med Commun"},{"key":"7630_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12734-4","volume":"24","author":"Q Wang","year":"2024","unstructured":"Wang Q, Ketteler S, Bagheri S, Ebrahimifard A, Luster M, Librizzi D, et al. Diagnostic efficacy of [(99m)Tc]Tc-PSMA SPECT\/CT for prostate cancer: a meta-analysis. BMC Cancer. 2024;24:982. https:\/\/doi.org\/10.1186\/s12885-024-12734-4.","journal-title":"BMC Cancer"},{"key":"7630_CR24","doi-asserted-by":"publisher","unstructured":"Schmidkonz C, Hollweg C, Beck M, Reinfelder J, Goetz TI, Sanders JC, et al. (99m) Tc-MIP-1404-SPECT\/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer. Prostate. 2018;78:54\u201363. https:\/\/doi.org\/10.1002\/pros.23444.","DOI":"10.1002\/pros.23444"},{"key":"7630_CR25","doi-asserted-by":"publisher","first-page":"366","DOI":"10.2967\/jnumed.124.269319","volume":"66","author":"T Derlin","year":"2025","unstructured":"Derlin T, Widjaja L, Harke NN, Czerner C, Weiberg D, Ross TL, et al. (99m)Tc-MIP-1404 SPECT\/CT companion diagnostic for (177)Lu-PSMA therapy in metastatic castration-resistant prostate cancer. J Nucl Med. 2025;66:366\u201372. https:\/\/doi.org\/10.2967\/jnumed.124.269319.","journal-title":"J Nucl Med"},{"key":"7630_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2967\/jnumed.122.264296","volume":"64","author":"GR Cook","year":"2023","unstructured":"Cook GR, Wong W, Sanghera B, Mangar S, Challapalli A, Bahl A, et al. Eligibility for (177)Lu-PSMA therapy depends on the choice of companion diagnostic tracer: A comparison of (68)Ga-PSMA-11 and (99m)Tc-MIP-1404 in metastatic Castration-Resistant prostate cancer. J Nucl Med. 2023;64:227\u201331. https:\/\/doi.org\/10.2967\/jnumed.122.264296.","journal-title":"J Nucl Med"},{"key":"7630_CR27","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s12149-019-01400-6","volume":"33","author":"C Schmidkonz","year":"2019","unstructured":"Schmidkonz C, Goetz TI, Kuwert T, Ritt P, Prante O, B\u00e4uerle T, et al. PSMA SPECT\/CT with (99m)Tc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels. Ann Nucl Med. 2019;33:891\u20138. https:\/\/doi.org\/10.1007\/s12149-019-01400-6.","journal-title":"Ann Nucl Med"},{"key":"7630_CR28","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2967\/jnumed.122.264743","volume":"64","author":"P Olivier","year":"2023","unstructured":"Olivier P, Giraudet AL, Skanjeti A, Merlin C, Weinmann P, Rudolph I, et al. Phase III study of (18)F-PSMA-1007 versus (18)F-fluorocholine PET\/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, crossover multicenter study. J Nucl Med. 2023;64:579\u201385. https:\/\/doi.org\/10.2967\/jnumed.122.264743.","journal-title":"J Nucl Med"},{"key":"7630_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.22038\/aojnmb.2019.43943.1293","volume":"8","author":"B Albalooshi","year":"2020","unstructured":"Albalooshi B, Al Sharhan M, Bagheri F, Miyanath S, Ray B, Muhasin M, et al. Direct comparison of (99m)Tc-PSMA SPECT\/CT and (68)Ga-PSMA PET\/CT in patients with prostate cancer. Asia Ocean J Nucl Med Biol. 2020;8:1\u20137. https:\/\/doi.org\/10.22038\/aojnmb.2019.43943.1293.","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"7630_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000003410","volume":"46","author":"B Fallahi","year":"2021","unstructured":"Fallahi B, Khademi N, Karamzade-Ziarati N, Fard-Esfahani A, Emami-Ardekani A, Farzanefar S, et al. 99mTc-PSMA SPECT\/CT versus 68Ga-PSMA PET\/CT in the evaluation of metastatic prostate cancer. Clin Nucl Med. 2021;46:e68\u201374. https:\/\/doi.org\/10.1097\/rlu.0000000000003410.","journal-title":"Clin Nucl Med"},{"key":"7630_CR31","first-page":"332","volume":"8","author":"FO Garc\u00eda-P\u00e9rez","year":"2018","unstructured":"Garc\u00eda-P\u00e9rez FO, Davanzo J, L\u00f3pez-Buenrostro S, Santos-Cuevas C, Ferro-Flores G, J\u00edmenez-R\u00edos MA, et al. Head to head comparison performance of (99m)Tc-EDDA\/HYNIC-iPSMA SPECT\/CT and (68)Ga-PSMA-11 PET\/CT a prospective study in biochemical recurrence prostate cancer patients. Am J Nucl Med Mol Imaging. 2018;8:332\u201340.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"7630_CR32","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/pros.23379","volume":"77","author":"IO Lawal","year":"2017","unstructured":"Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT\/CT in prostate carcinoma: a comparative analysis with Ga-68 PSMA PET\/CT. Prostate. 2017;77:1205\u201312. https:\/\/doi.org\/10.1002\/pros.23379.","journal-title":"Prostate"},{"key":"7630_CR33","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4103\/ijnm.ijnm_8_24","volume":"39","author":"M Ora","year":"2024","unstructured":"Ora M, Saini VK, Dixit M, Singh UP, Gambhir S. An analysis of the diagnostic performance of Tc-99m PSMA SSPECT\/CT in biochemically recurrent prostate cancer compared with Ga-68 PSMA PET\/CT: a single-center, prospective study. Indian J Nucl Med. 2024;39:170\u20136. https:\/\/doi.org\/10.4103\/ijnm.ijnm_8_24.","journal-title":"Indian J Nucl Med"},{"key":"7630_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.remnie.2023.06.003","volume":"42","author":"A Saudi","year":"2023","unstructured":"Saudi A, Takhar P, Aljabery F, Ochoa-Figueroa M. (99m)Tc-MIP-1404 CZT SPECT\/CT versus (68)Ga\/PSMA-11 PET\/CT: imaging of prostate cancer metastasis. Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition). 2023;42:413\u20135. https:\/\/doi.org\/10.1016\/j.remnie.2023.06.003.","journal-title":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"},{"key":"7630_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2023.110803","volume":"163","author":"ML Schnitzer","year":"2023","unstructured":"Schnitzer ML, Buchner J, Biechele G, Grawe F, Ingenerf M, von M\u00fcnchhausen N, et al. Economic evaluation of 18F-FDG PET\/CT, MRI and CE-CT in selection of colorectal liver metastases eligible for ablation \u2013 a cost-effectiveness analysis. Eur J Radiol. 2023;163:110803. https:\/\/doi.org\/10.1016\/j.ejrad.2023.110803.","journal-title":"Eur J Radiol"},{"key":"7630_CR36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s12471-014-0558-4","volume":"22","author":"EE van der Wall","year":"2014","unstructured":"van der Wall EE. Cost analysis favours SPECT over PET and CTA for evaluation of coronary artery disease: the SPARC study. Neth Heart J. 2014;22:257\u20138. https:\/\/doi.org\/10.1007\/s12471-014-0558-4.","journal-title":"Neth Heart J"},{"key":"7630_CR37","first-page":"251597","volume":"66","author":"T Khan","year":"2025","unstructured":"Khan T, Khan F, Patil S, Schaison F, Subtirelu R, Revheim M-e, et al. Barriers to equitable access: A systematic examination of PET\/CT imaging disparities. J Nucl Med. 2025;66:251597.","journal-title":"J Nucl Med"},{"key":"7630_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21608\/egyjnm.2022.164007.1065","volume":"25","author":"IE Saad Ahmed","year":"2022","unstructured":"Saad Ahmed IE, Availability, Affordability Of PET, Tracers. The challenges and opportunities in developing countries. Egypt J Nuclear Med. 2022;25:1\u20137. https:\/\/doi.org\/10.21608\/egyjnm.2022.164007.1065.","journal-title":"Egypt J Nuclear Med"},{"key":"7630_CR39","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s00330-010-2025-y","volume":"21","author":"PF H\u00f8ilund-Carlsen","year":"2011","unstructured":"H\u00f8ilund-Carlsen PF, Gerke O, Vilstrup MH, Nielsen AL, Thomassen A, Hess S, et al. PET\/CT without capacity limitations: a Danish experience from a European perspective. Eur Radiol. 2011;21:1277\u201385. https:\/\/doi.org\/10.1007\/s00330-010-2025-y.","journal-title":"Eur Radiol"},{"key":"7630_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00259-019-04452-y","volume":"47","author":"ME Mayerhoefer","year":"2020","unstructured":"Mayerhoefer ME, Prosch H, Beer L, Tamandl D, Beyer T, Hoeller C, et al. PET\/MRI versus PET\/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. Eur J Nucl Med Mol Imaging. 2020;47:51\u201360. https:\/\/doi.org\/10.1007\/s00259-019-04452-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7630_CR41","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1055\/s-0042-1744200","volume":"21","author":"K Liepe","year":"2022","unstructured":"Liepe K, Baehr M. Tc-99m-PSMA-SPECT\/CT is superior to Tc-99m-MDP-SPECT\/CT in the staging of prostatic cancer with osseous metastases after external beam radiotherapy. World J Nuclear Med. 2022;21:62\u20134. https:\/\/doi.org\/10.1055\/s-0042-1744200.","journal-title":"World J Nuclear Med"},{"key":"7630_CR42","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1055\/a-1233-8523","volume":"59","author":"K Liepe","year":"2020","unstructured":"Liepe K, Baehr M, Kuhn B. False-positive findings in inflammatory processes using 99mTc-PSMA. Nuklearmedizin. 2020;59:443\u20134. https:\/\/doi.org\/10.1055\/a-1233-8523.","journal-title":"Nuklearmedizin"},{"key":"7630_CR43","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1055\/a-2578-7222","volume":"64","author":"M Baehr","year":"2025","unstructured":"Baehr M, Dietrich I, Liepe K. [99mTc]Tc-PSMA SPECT\/CT is a promising tool in the staging of renal cell carcinoma. Nuklearmedizin. 2025;64:274\u20136. https:\/\/doi.org\/10.1055\/a-2578-7222.","journal-title":"Nuklearmedizin"},{"key":"7630_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/0470114754","volume-title":"An introduction to categorical data Analysis, second edition","author":"A Agresti","year":"2007","unstructured":"Agresti A. An introduction to categorical data Analysis, second edition. Hoboken, New Jersey, USA: John Wiley & Sons, Inc; 2007."},{"key":"7630_CR45","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1001\/jama.2017.13276","volume":"318","author":"K Yadav","year":"2017","unstructured":"Yadav K, Lewis RJ. Gatekeeping strategies for avoiding false-positive results in clinical trials with many comparisons. JAMA. 2017;318:1385\u20136.","journal-title":"JAMA"},{"key":"7630_CR46","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/01621459.1983.10477989","volume":"78","author":"CR Mehta","year":"1983","unstructured":"Mehta CR, Patel NR. A network algorithm for performing fisher\u2019s exact test in r \u00d7 c contingency tables. J Am Stat Assoc. 1983;78:427\u201334. https:\/\/doi.org\/10.1080\/01621459.1983.10477989.","journal-title":"J Am Stat Assoc"},{"key":"7630_CR47","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/sim.3495","volume":"28","author":"F Bretz","year":"2009","unstructured":"Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Stat Med. 2009;28:586\u2013604.","journal-title":"Stat Med"},{"key":"7630_CR48","first-page":"1","volume":"1","author":"H Abdi","year":"2010","unstructured":"Abdi H. Holm\u2019s sequential bonferroni procedure. Encyclopedia Res Des. 2010;1:1\u20138.","journal-title":"Encyclopedia Res Des"},{"key":"7630_CR49","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4028\/www.scientific.net\/AMM.611.115","volume":"611","author":"E Ostertagova","year":"2014","unstructured":"Ostertagova E, Ostertag O, Kov\u00e1\u010d J. Methodology and application of the Kruskal-Wallis test. Appl Mech Mater. 2014;611:115\u201320.","journal-title":"Appl Mech Mater"},{"key":"7630_CR50","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3102\/10769986023002170","volume":"23","author":"A Vargha","year":"1998","unstructured":"Vargha A, Delaney HD. The Kruskal-Wallis test and stochastic homogeneity. J Educ Behav Stat. 1998;23:170\u201392. https:\/\/doi.org\/10.3102\/10769986023002170.","journal-title":"J Educ Behav Stat"},{"key":"7630_CR51","doi-asserted-by":"crossref","unstructured":"Agbangba CE, Aide ES, Honfo H, Kakai RG. On the use of post-hoc tests in environmental and biological sciences: A critical review. Heliyon. 2024;10.","DOI":"10.1016\/j.heliyon.2024.e25131"},{"key":"7630_CR52","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5:856\u201363. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096.57.","journal-title":"JAMA Oncol"},{"key":"7630_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.redii.2022.100021","volume":"5","author":"J Jiang","year":"2023","unstructured":"Jiang J, Chen L, Ji X, Zheng X, Hong J, Tang K. ((18)F)-PSMA-1007PET\/CT in patients with biochemical recurrence after radical prostatectomy: diagnostic performance and impact on treatment management. Res Diagn Interv Imaging. 2023;5:100021. https:\/\/doi.org\/10.1016\/j.redii.2022.100021.58.","journal-title":"Res Diagn Interv Imaging"},{"key":"7630_CR54","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4103\/1450-1147.207286","volume":"16","author":"J Yoon","year":"2017","unstructured":"Yoon J, Ballas L, Desai B, Jadvar H. Prostate-specific antigen and Prostate-Specific antigen kinetics in predicting (18)F-sodium fluoride positron emission tomography-computed tomography positivity for first bone metastases in patients with biochemical recurrence after radical prostatectomy. World J Nucl Med. 2017;16:229\u201336. https:\/\/doi.org\/10.4103\/1450-1147.207286.","journal-title":"World J Nucl Med"},{"key":"7630_CR55","doi-asserted-by":"publisher","unstructured":"Knoll P, Kotalova D, K\u00f6chle G, Kuzelka I, Minear G, Mirzaei S, et al. Comparison of advanced iterative reconstruction methods for SPECT\/CT. Z Med Phys. 2012;22:58\u201369. https:\/\/doi.org\/10.1016\/j.zemedi.2011.04.007.56.\u00a0","DOI":"10.1016\/j.zemedi.2011.04.007.56"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07630-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07630-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07630-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:38:44Z","timestamp":1771479524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07630-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7630"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07630-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Only patients who routinely used PSMA-SPECT\/CT were included in the publication, it is a retrospective study.\u00a0","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Responsibilities of Authors"}},{"value":"All patients were informed about the diagnostic procedure.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"\u00a0All data are anonymised.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Author 1 is a consultant for the company Rotop, Author 2 and 3 have no conflict of interest.\u00a0","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}